Dengfeng Kang
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Exclusive enteral nutrition and infliximab combination therapy are superior to monotherapy in inducing endoscopic response in active adult Crohn's disease.
Journal: Therapeutic advances in gastroenterology
Published: January 05, 2026
Microbiota-derived IPA alleviates intestinal mucosal inflammation through upregulating Th1/Th17 cell apoptosis in inflammatory bowel disease.
Journal: Gut microbes
Published: February 16, 2025
YDJC restrains Th1 cell differentiation by blocking SREBP2-mediated cholesterol biosynthesis to alleviate mucosal inflammation in inflammatory bowel disease.
Journal: Cellular & molecular immunology
Published: October 31, 2024
Dysregulation of Farnesoid X Receptor on Neutrophil Homeostasis Exacerbates Intestinal Inflammation via the mTORC1-Glycolysis Signaling Pathway.
Journal: MedComm
Published: September 18, 2024
Circadian clock component PER2 negatively regulates CD4+ T cell IFN-γ production in ulcerative colitis.
Journal: Mucosal immunology
Published: December 14, 2023
Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn's disease.
Journal: Therapeutic advances in gastroenterology
Published: October 09, 2023
Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease.
Journal: Frontiers in pharmacology
Published: April 06, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026